Answers are grounded in this paper and cite their sources.
Alzheimer’s disease (AD) is a multifactorial neurodegenerative disorder, driving the search for multitarget-directed ligands (MTDLs) able to modulate multiple pathological pathways. Since amphibians represent a rich source of bioactive peptides, skin extracts from Scinax nasicus and Dendropsophus nanus, classified by sex, developmental stage, and season, were evaluated against key AD-related mechanisms, including cholinesterase inhibition, antioxidant activity, and Fe2+ chelation. Subsequently, a rational discovery workflow was implemented, integrating extract-level chemical characterization and bioactivity screening with the sequence identification of the main components and a novel in silico algorithm-based prioritization. This strategy, formalized through the Multi-Target Therapeutic Potential Score (MTTP-Score), served as a rational filter to produce a focused synthetic library, significantly minimizing experimental time and cost. Peptides derived from D. nanus (Dn) displayed the most promising multitarget candidates. Dn-7 combined sub-micromolar dual cholinesterase inhibition (IC50 = 0.32 and 1.2 µM for AChE and BChE, respectively) with highly efficient Fe2+ chelation (EC50 = 39 µM), representing the highest MTDL activity reported for an amphibian peptide. Dn-18 emerged as a moderate butyrylcholinesterase inhibitor with strong metal chelating capacity. Overall, this study establishes a pipeline for the rational discovery of peptide-based MTDL scaffolds for AD.
No takes yet. Share an insight, caveat, or question.
Rietmann et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: